221 related articles for article (PubMed ID: 31144016)
1. Counting Steps: A New Way to Monitor Patients with Pulmonary Arterial Hypertension.
Sehgal S; Chowdhury A; Rabih F; Gadre A; Park MM; Li M; Wang X; Highland KB;
Lung; 2019 Aug; 197(4):501-508. PubMed ID: 31144016
[TBL] [Abstract][Full Text] [Related]
2. Physical activity in incident patients with pulmonary arterial and chronic thromboembolic hypertension.
Saxer S; Lichtblau M; Berlier C; Hasler ED; Schwarz EI; Ulrich S
Lung; 2019 Oct; 197(5):617-625. PubMed ID: 31263960
[TBL] [Abstract][Full Text] [Related]
3. The longitudinal use of EmPHasis-10 and CAMPHOR questionnaire health-related quality of life scores in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Hendriks PM; van Thor MCJ; Wapenaar M; Chandoesing P; van den Toorn LM; van den Bosch AE; Post MC; Boomars KA
Respir Med; 2021 Sep; 186():106525. PubMed ID: 34218166
[TBL] [Abstract][Full Text] [Related]
4. Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP).
Stollfuss B; Richter M; Drömann D; Klose H; Schwaiblmair M; Gruenig E; Ewert R; Kirchner MC; Kleinjung F; Irrgang V; Mueller C
J Med Internet Res; 2021 Oct; 23(10):e25163. PubMed ID: 34623313
[TBL] [Abstract][Full Text] [Related]
5. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1.
Frantz RP; McDevitt S; Walker S
J Heart Lung Transplant; 2012 Aug; 31(8):811-6. PubMed ID: 22759797
[TBL] [Abstract][Full Text] [Related]
6. The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension.
Wronski SL; Mordin M; Kelley K; Anguiano RH; Classi P; Shen E; Manaker S
Lung; 2020 Feb; 198(1):65-86. PubMed ID: 31722043
[TBL] [Abstract][Full Text] [Related]
7. B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension.
Takatsuki S; Wagner BD; Ivy DD
Congenit Heart Dis; 2012; 7(3):259-67. PubMed ID: 22325151
[TBL] [Abstract][Full Text] [Related]
8. Association between meeting daily step count goals with ambulatory function and quality of life in patients with claudication.
Gardner AW; Montgomery PS; Wang M; Shen B
J Vasc Surg; 2021 Jun; 73(6):2105-2113. PubMed ID: 33253870
[TBL] [Abstract][Full Text] [Related]
9. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
[TBL] [Abstract][Full Text] [Related]
10. Step climbing capacity in patients with pulmonary hypertension.
Fox BD; Langleben D; Hirsch A; Boutet K; Shimony A
Clin Res Cardiol; 2013 Jan; 102(1):51-61. PubMed ID: 22875547
[TBL] [Abstract][Full Text] [Related]
11. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
[TBL] [Abstract][Full Text] [Related]
12. Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study.
Deng X; Jin B; Li S; Li Y; Zhou H; Wu Y; Yan M; Hu Y; Qiu Q; Zhang G; Zheng X
Clin Respir J; 2019 Nov; 13(11):693-699. PubMed ID: 31419027
[TBL] [Abstract][Full Text] [Related]
13. Comparison of questionnaire and accelerometer-based assessments of physical activity in patients with heart failure with preserved ejection fraction: clinical and prognostic implications.
Schmidt C; Santos M; Bohn L; Delgado BM; Moreira-Gonçalves D; Leite-Moreira A; Oliveira J
Scand Cardiovasc J; 2020 Apr; 54(2):77-83. PubMed ID: 31894707
[No Abstract] [Full Text] [Related]
14. Biological serum markers in the management of pediatric pulmonary arterial hypertension.
Van Albada ME; Loot FG; Fokkema R; Roofthooft MT; Berger RM
Pediatr Res; 2008 Mar; 63(3):321-7. PubMed ID: 18287971
[TBL] [Abstract][Full Text] [Related]
15. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension.
Frantz RP; Benza RL; Kjellström B; Bourge RC; Barst RJ; Bennett TD; McGoon MD
J Heart Lung Transplant; 2008 Jul; 27(7):780-8. PubMed ID: 18582809
[TBL] [Abstract][Full Text] [Related]
16. Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study.
Gerhardt F; Dumitrescu D; Gärtner C; Beccard R; Viethen T; Kramer T; Baldus S; Hellmich M; Schönau E; Rosenkranz S
Heart; 2017 Apr; 103(8):592-598. PubMed ID: 28100544
[TBL] [Abstract][Full Text] [Related]
17. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
[TBL] [Abstract][Full Text] [Related]
18. The association of N-terminal pro-brain-type natriuretic peptide with hemodynamics and functional capacity in therapy-naive precapillary pulmonary hypertension: results from a cohort study.
Berghaus TM; Kutsch J; Faul C; von Scheidt W; Schwaiblmair M
BMC Pulm Med; 2017 Dec; 17(1):167. PubMed ID: 29202745
[TBL] [Abstract][Full Text] [Related]
19. Submaximal exercise testing may be superior to the 6-min walk test in assessing pulmonary arterial hypertension disease severity.
Neal JE; Lee AS; Burger CD
Clin Respir J; 2014 Oct; 8(4):404-9. PubMed ID: 24308300
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]